The community pharmacy
All the benchmarks and programs finally collide at the counter of a neighborhood pharmacy. Here's what actually happens when a prescription is filled — and why so many independents are closing despite filling more scripts than ever.
How one prescription gets paid
When a pharmacy fills a covered script, the payment comes from two pockets:
- The patient's copay — collected at pickup.
- The plan's reimbursement — sent later by the PBM.
The PBM's reimbursement is a benchmark for the drug (AWP-minus, or a MAC ceiling for generics) plus a dispensing fee. The pharmacy's profit — or loss — is that total minus what it paid to buy the drug (its NADAC-ish acquisition cost) and minus the cost of actually running the pharmacy.
The underwater claim
Because PBMs set the reimbursement (via their private MAC lists) and the pharmacy has no say, the reimbursement can come in below what the pharmacy paid for the drug. The pharmacy loses money on the fill and often can't find out why until after it's dispensed. Do that enough times and volume can't save you.
The PBM in the middle
A handful of pharmacy benefit managers — the largest three process the majority of US prescriptions — sit between plans, manufacturers, and pharmacies. They decide the formulary, negotiate manufacturer rebates, set pharmacy reimbursement, and often own mail-order and specialty pharmacies that compete with the very pharmacies they pay. Two practices draw the most scrutiny:
- Spread pricing: the PBM charges the plan more than it pays the pharmacy and keeps the difference — the “spread.”
- DIR fees (Direct and Indirect Remuneration): for years, PBMs clawed back money from pharmacies weeks or months after a fill, making it nearly impossible to know a script's true profit at the time. A 2024 CMS rule now requires those price concessions to be reflected at the point of sale — a meaningful, if partial, fix.
PSAOs — how independents get a seat at the table
A single independent pharmacy has almost no leverage to negotiate with a PBM that processes a billion claims. So independents band together through a Pharmacy Services Administrative Organization (PSAO).
A PSAO negotiates and manages PBM contracts on behalf of hundreds or thousands of member pharmacies at once, handles the paperwork of joining payer networks, and helps with reconciliation (checking that pharmacies were actually paid what the contract promised). Most PSAOs are tied to the big drug wholesalers — a pharmacy's buying group and its contracting group are often the same corporate family.
A PSAO gives a corner pharmacy collective bargaining power it could never have alone. What it generally can't do is change the underlying economics — if a PBM's take-it-or-leave-it network rate is below cost, the PSAO's job is mostly to get the best available version of a hard deal.
Why this adds up to closures
Put it together: reimbursement benchmarks the pharmacy doesn't control, MAC lists it can't see, clawbacks it can't predict, and dispensing fees that often don't cover the real cost of a pharmacist's time. A pharmacy can fill record volume and still lose money on a large share of claims. That math — not lack of demand — is what's behind the wave of independent and even chain closures, and the growing “pharmacy deserts” in rural and low-income areas.
Where transparency helps
Every one of these problems is worse in the dark. Knowing a drug's real acquisition cost (NADAC), which manufacturers make it, whether it's in shortage, and how its price is moving is the starting point for a pharmacist to spot a bad reimbursement before it sinks them. That's the whole reason DrugDashboards exists.